Survival from Bladder Cancer in England and Wales
Author Information
Author(s): Whelan P
Primary Institution: Pyrah Department of Oncology, St James' Hospital
Conclusion
Survival rates for bladder cancer have not significantly changed between the late 1980s and 2001 due to unchanged treatment approaches.
Supporting Evidence
- The study highlighted that over half of bladder cancer patients experience recurrence.
- It noted that 25% of new bladder cancer cases are muscle-invasive at presentation.
- The research indicated that the standard treatment for high-risk non-muscle-invasive bladder cancer is Bacillus Calmette-Guerin (BCG) therapy.
Takeaway
This study looked at how people with bladder cancer in England and Wales have survived over the years. It found that not much has changed in how well they do since the late 1980s.
Methodology
The study analyzed data from various clinical trials and cancer registries to assess survival rates and treatment outcomes.
Potential Biases
Potential biases may arise from the reliance on historical data and the variability in treatment approaches across different hospitals.
Limitations
The study's findings may be affected by misclassification of cases and the lack of consistent pathological reporting.
Participant Demographics
The study included patients diagnosed with bladder cancer in England and Wales, with a focus on both non-muscle-invasive and muscle-invasive cases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website